Nu o, MV, Fern ndez-Le n, A, Alvarado, PM, Stefaneli, P, Calahorro, MC, Park, HS, Barros-Membrilla, A, Prudencio, GG, Camacho, V, Duch, J, Soldevila-Lozano, C, Echevarne, SC, Lopez, BM, Barranco, IC, Mendez, HC, Macias, HC, Flotats, A. ^[18F]FDG-PET/CT in Giant Cell Arteritis. Which vascular segmental quantitative parameter is most useful?. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2024; 51DOI:. PMID:. IF:7.600(Q1/1D).

Camacho, V, Vaqu , L, Stefaneli, P, Calls, M, Fernandez, A, Duch, J, Barroeta, I, Carmona, M, Velasco, M, Soldevila, C, Guzm n, G, Castej n, S, Bejanin, A, Lle , A, Fortea, J, Flotats, A. Tau PET deposition measured by ^[18F]PI-2620 increases along the Alzheimer's disease continuum in Down Syndrome. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2024; 51DOI:. PMID:. IF:7.600(Q1/1D).

Casanovas, MM, L pez, J, Jimenez-Fonseca, P, Pubul, V, Bello, P, Garc a-Burillo, A, Valverde, R, Llana, B, Percovich, J, Soldevila, C, Arbizu, J, Pi eiro, A, Castell n, M, Ordu a, P, Cano, J, Tabuenca, M, Rodado, S, Garcia-Ca amaque, L, Nevares, M, Balaguer, D, Gomez, D, Hernando, J, Repetto, A, Nogareda, Z, Carmona-Bayonas, A. Prediction of patient progression-free survival with ¹⁷⁷Lu-DOTATATE in clinical practice: NEPTUNESEPTRALU model for patient selection. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2024; 51DOI:. PMID:. IF:7.600(Q1/1D).

Mormandi, PS, Ballester, PZ, Calls, M, Aguirre, SR, Leon, AF, Guzman, G, Lozano, CS, Castejon, S, Nu o, MV, Duch, J, Fortea, J, Camacho, V, Giralt, AF. Interobserver agreement in the visual analysis of brain PET/CT studies with Tau tracer [¹⁸F]PI-2620 in patients with Down syndrome.. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2024; 51DOI:. PMID:. IF:7.600(Q1/1D).